Back to News
Market Impact: 0.25
AnnJi Pharmaceutical fait passer l'AJ201 à l'étude pivot de phase III ROMA-KD pour le traitement de l'atrophie musculaire spinale et bulbaire (SBMA)
Source: PR Newswire
Healthcare & Biotech
AJ201 (rosolutamide), an experimental oral small molecule for SBMA, is described as the only known treatment for the condition worldwide currently in Phase III development. It is designed to act on multiple disease mechanisms; the excerpt provides no trial results or efficacy data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- McKesson and CD&R agree to acquire Option Care Health for $5.8 billion
- LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation